v3.26.1
Segment Reporting (Tables)
12 Months Ended
Dec. 31, 2025
Segment Reporting  
Schedule of segment significant expense categories

  ​ ​ ​

Year Ended December 31, 

2025

2024

Grant income

$

23,406

$

19,549

Less:

 

 

Clinical programs

25,133

27,675

R&D personnel costs(1)

7,743

9,672

Preclinical programs

446

810

Manufacturing

2,543

2,241

Other research and development expenses

230

198

General and administrative expenses(2)

9,617

9,622

Equity-based compensation

2,087

3,748

Other segment items(3)

 

(906)

 

(446)

Segment and consolidated net loss

$

(23,487)

$

(33,971)

(1) R&D Personnel costs exclude equity-based compensation

(2) General and administrative expenses exclude equity-based compensation

(3) Other segment items include, Other income, net, Interest expense and Loss on currency translation from liquidation of subsidiary.